ClinicalTrials.gg
RecruitingNCT06453902Updated Feb 21, 2025

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

A Phase 2 interventional study of TGRX-678 in Chronic Myeloid Leukemia and Accelerated Phase CML, sponsored by Shenzhen TargetRx, Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Shenzhen TargetRx, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China — 11 open to participants now, 14 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China.

Planned enrollment
31st of 37
40 · median 144
Started
2024
with 3 others
Phase 2
10 of 49
2 open now
Primary completion
2026-06
later than 2 of 13 live
Registered
41st of 49
by date
Lead sponsor
3 of 49
Shenzhen TargetRx, Inc.

Among the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, this one is the 31st largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 2 of the 13 other live ones, and was the 41st registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

11 of the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, or all of them as a file.
02

Study summary

A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment

Read the detailed description

This Phase II study is of single-arm, open-label and multi-center designs to study safety and efficacy profiles of TGRX-678 in CML-AP patients. Patients need to have medical history of failing treatment(s) from third-generation TKI drugs. Patients with or without T315I mutation is enrolled.

03

Conditions studied

  • Chronic Myeloid Leukemia
  • Accelerated Phase CML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to consent
  • 18 years of age or above at time of screening; both sexes eligible
  • or refactory from 3rd-generation Tyrosine kinase inhibitor (TKI) treatment
  • For patients without T315I mutation, the patients must received 1st, 2nd and 3rd generation TKI
  • For patients with T315I mutation, the patients much received Olverembatinib or Ponatinib treatment
  • Diagnosis of CML-AP by bone marrow morphological test, molecular biology test or cytogenetic tests
  • score \</=2
  • Minimum of at least 3 months
  • Adequate hematological indicators
  • Adequate kidney function
  • Adequate liver function
  • Adequate coagulation function
  • Adequate pancreatic function
  • Adequate as confirmed by (ECG) test
  • Negative pregnancy result at screening for female patients of
  • Willing to take measure during the study (For male and female patients of child-bearing potential)

Exclusion criteria

Exclusion Criteria:

  • Reception of TKI treatment or presence of unrecovered TKI treatment related non-hematological adverse events within 7 days of first dose
  • Reception of other anti-tumor treatments
  • In need for immune suppressive treatment
  • Usage of drugs associated with Torsades de Pointes within 1 months before screening
  • Presence of other medical conditions that require using treatment that may have drug-drug interaction with the drug
  • History of hemapoietic stem cell transplant
  • Presence of active central nervous system conditions
  • CML-AP patients who already reached major hematological response
  • CML-AP patients who used to progress to Blast Phase (BP)
  • Presence or having uncontrolled condition for cardiovascular diseases
  • History of any heart or cardiovascular conditions (except for patients with hypertension which is controlled by anti-hypertensive drugs, and blood pressure is controlled at no higher than 160/100 mmHg for 1 months before screening)
  • Usage of any Traditional Chinese Medicine indicated for anti-tumor purpose 2 weeks before first dose
  • Severe hemorrhagic disease unrelated to CML
  • History of severe cardiovascular condition during past TKI treatment for CML
  • History of pancreatic inflammation or alcohol abuse within 3 years before first dose
  • Uncontrolled Hypertriglyceridemia
  • Presence of malabsorption or other conditions that may affect drug absorption
  • Diagnosis of other primary malignant tumor within 5 years
  • Reception of major surgery 14 days before first dose
  • Presence of continuous or active infection (including , , )
  • Presence of other conditions that the investigators or medical monitor deem unfit for the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental: TGRX-678

    All patients with CML-AP to be treated with TGRX-678. Patients with T315I mutation or without T315I mutation will be assigned into separate cohorts for evaluation

    Drug: TGRX-678

Interventions

  • All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally

06

What researchers measure

Primary outcomes

  1. Major Hematologic Response (MaHR)

    Number of patients who reached, and rate of occurence of major hematologic response, including those who reached complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR and NEL are defined per China national treatment guideline for CML (ver. 2022). Indicators for hematologic responses will be obtained via peripheral blood tests.

    Time frame: At screening, on Day 1 of every treatment cycle (each cycle is 28 days) and at end of treatment; average of study duration is 3.5 years

Secondary outcomes

  1. Cytogenetic Response

    Number of patients who reached, and rate of occurence of cytogenetic response, including those with major cytogenetic response (MCyR) or complete cytogenetic response (CCyR). Cytogenetic responses are defined per China national treatment guideline for CML (ver. 2022). Indicators for cytogenetic responses will be obtained via bone marrow biopsy.

    Time frame: At screening, on Day 1 of cycle 2, cycle 4 and every 3 cycles afterwards of the treatment cycle (each cycle is 28 days) and at the end of treatment; average of study duration is 3.5 years

  2. Major Molecular Response (MMR)

    Number of patients who reached, and rate of occurence of MMR. Cytogenetic response is defined per China national treatment guideline for CML (ver. 2022). Indicators for molecular responses will be obtained via genetic testing on transcript levels of BCR-ABL gene.

    Time frame: At screening, on Day 1 of cycle 2, cycle 4 and every 3 cycles afterwards of the treatment cycle (each cycle is 28 days) and at the end of treatment; average of study duration is 3.5 years

  3. Time to Response (TTR)

    TTR defined by the time from the start of treatment to the first efficacy response; TTR as evaluated by investigator

    Time frame: At screening, on Day 1 of cycle 2, cycle 4 and every 3 cycles afterwards of the treatment cycle (each cycle is 28 days) and at the end of treatment; average of study duration is 3.5 years

  4. Duration of Response (DOR)

    DOR defined as the duration from first occurence of treatment response to progressive disease/relapse; DOR as evaluated by investigator

    Time frame: At screening, on Day 1 of cycle 2, cycle 4 and every 3 cycles afterwards of the treatment cycle (each cycle is 28 days) and at the end of treatment; average of study duration is 3.5 years

  5. Progression Free Survival (PFS)

    PFS defined as the time from enrollment to progressive disease or death of any cause; PFS as evaluated by investigator.

    Time frame: At screening, on Day 1 of cycle 2, cycle 4 and every 3 cycles afterwards of the treatment cycle (each cycle is 28 days) and at the end of treatment; average of study duration is 3.5 years

  6. Overall Survival (OS)

    OS defined as the time from enrollment to death of any cause; OS as evaluated by investigator

    Time frame: At screening, on Day 1 of cycle 2, cycle 4 and every 3 cycles afterwards of the treatment cycle (each cycle is 28 days) and at the end of treatment; average of study duration is 3.5 years

  7. Treatment Emergent Adverse Event (TEAE)

    To record and analyse the occurence and frequency of adverse events during the study

    Time frame: Through completion of the study, an average of 3.5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2026, 23 months after the start.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's planned 23 months is below that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 12, 2024
StartActual
Jul 15, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Apr 30, 2028
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06453902
Lead sponsor
Shenzhen TargetRx, Inc.
Collaborators
Peking University People's Hospital, Henan Cancer Hospital, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Soochow University, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, First Affiliated Hospital of Zhejiang University, Shenzhen Second People's Hospital, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Shengjing Hospital, Tongji Medical College,Huazhong University of Science &Techonlogy
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Jul 15, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Feb 21, 2025

Study contacts

Yingkun Lu
Contact
yingkun.lv@tjrbiosciences.com
18602219981
Qian Jiang, MD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meribatinib

Start the discussion